Healthcare & Life Sciences Government Affairs
Lanton Strategies International advises European and U.S. pharmaceutical, biotechnology, healthcare technology companies and trade associations on public policy and government affairs across the United States, European Union and United Kingdom.
U.S. federal and state policy
We help European companies understand how Congress, federal agencies and state governments shape reimbursement, drug pricing, market access and commercial operations. Our advisory work focuses on the business implications of legislative proposals and rulemaking, including developments at CMS and FDA.
Government affairs strategy
We help clients identify relevant policymakers, prioritize policy matters, prepare executive briefings and develop government engagement strategies. We advise on legislative monitoring, stakeholder engagement, coalition strategy and policy advocacy planning.
Healthcare policy expertise
Pharmaceutical pricing and reimbursement policy
Medicare, Medicaid, PBM and 340B developments
Biotechnology, healthcare innovation and technology policy
Federal and state healthcare legislation and regulation
Transatlantic trade and regulatory developments
Our Amsterdam platform connects European business priorities with U.S. policy expertise. Explore our U.S. market entry advisory or contact LSI to discuss your policy priorities.